Garde Capital’s Idexx Laboratories IDXX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$316K Hold
600
0.01% 197
2026
Q1
$337K Hold
600
0.02% 156
2025
Q4
$406K Sell
600
-5
-0.8% -$3.4K 0.02% 159
2025
Q3
$387K Hold
605
0.02% 180
2025
Q2
$324K Hold
605
0.02% 184
2025
Q1
$254K Sell
605
-1
-0.2% -$434 0.01% 200
2024
Q4
$251K Hold
606
0.02% 193
2024
Q3
$306K Hold
606
0.02% 173
2024
Q2
$295K Sell
606
-16
-3% -$8.03K 0.02% 172
2024
Q1
$335K Sell
622
-30
-5% -$16.4K 0.02% 165
2023
Q4
$362K Buy
652
+31
+5% +$14.6K 0.03% 148
2023
Q3
$272K Buy
621
+5
+0.8% +$2.49K 0.02% 173
2023
Q2
$309K Hold
616
0.03% 185
2023
Q1
$308K Hold
616
0.03% 148
2022
Q4
$251K Hold
616
0.03% 156
2022
Q3
$201K Hold
616
0.03% 162
2022
Q2
$216K Hold
616
0.03% 179
2022
Q1
$337K Hold
616
0.03% 156
2021
Q4
$406K Hold
616
0.04% 151
2021
Q3
$383K Buy
616
+16
+3% +$10.8K 0.04% 141
2021
Q2
$379K Hold
600
0.04% 141
2021
Q1
$294K Hold
600
0.03% 149
2020
Q4
$299K Hold
600
0.04% 148
2020
Q3
$236K Buy
+600
New +$222K 0.04% 148

Other funds holding IDXX

Garde Capital's IDXX Position: Q2 2026 in Review

Garde Capital held its Idexx Laboratories (IDXX) position steady in Q2 2026 at 600 shares worth $316K. The position accounts for 0.01% of the portfolio, ranked #197.

Garde Capital first reported a position in IDXX in Q3 2020 and has held it in 24 quarters since. The position peaked at $406K in Q4 2021. 773 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

  • Garde Capital held 600 shares of Idexx Laboratories worth $316K as of Q2 2026.
  • Garde Capital left its Idexx Laboratories share count unchanged in Q2 2026.
  • Idexx Laboratories made up 0.01% of Garde Capital's portfolio in Q2 2026, its #197 holding.
  • Garde Capital first reported a position in Idexx Laboratories in Q3 2020 and has held it in 24 quarters since.
  • Garde Capital's Idexx Laboratories position peaked at $406K in Q4 2021.
  • 773 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Garde Capital's 13F filing for Q2 2026, filed 31 Jul 2026.